Trending

multiple myeloma

EU regulators to fast-track Janssen’s multiple myeloma CAR-T

EU regulators to fast-track Janssen’s multiple myeloma CAR-T

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage

X

EU regulators to fast-track Janssen’s multiple myeloma CAR-T

https://pharmaphorum.com/news/eu-regulators-to-fast-track-janssens-multiple-myeloma-car-t/

GSK mulls filings for multiple myeloma drug

GSK mulls filings for multiple myeloma drug

GlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost

X

GSK mulls filings for multiple myeloma drug

https://pharmaphorum.com/news/gsk-mulls-filings-for-multiple-myeloma-drug/

Question marks over AbbVie/Roche’s venetoclax after safety scare

Question marks over AbbVie/Roche’s venetoclax after safety scare

AbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a

X

Question marks over AbbVie/Roche’s venetoclax after safety scare

https://pharmaphorum.com/news/question-marks-over-abbvie-roches-venetoclax-after-aml-safety-scare/

NICE backs interim funding for J&J/Takeda myeloma regimen

NICE backs interim funding for J&J/Takeda myeloma regimen

A three-drug regimen for multiple myeloma based on Johnson & Johnson’s Darzalex, Takeda’s Velcade and dexamethasone will be

X

NICE backs interim funding for J&J/Takeda myeloma regimen

https://pharmaphorum.com/news/nice-backs-interim-funding-for-jj-takeda-myeloma-regimen/

Advisers urge FDA to delay decision on Karyopharm cancer drug

Advisers urge FDA to delay decision on Karyopharm cancer drug

Advisers to the US drugs regulator have said a decision on whether to approve Karyopharm’s multiple myeloma combination

X

Advisers urge FDA to delay decision on Karyopharm cancer drug

https://pharmaphorum.com/news/advisers-urge-fda-to-delay-decision-on-karyopharm-cancer-drug/

Sanofi’s Darzalex rival hits the mark in phase 3 trial

Sanofi’s Darzalex rival hits the mark in phase 3 trial

Johnson & Johnson’s Darzalex multiple myeloma drug has just become a blockbuster – but it could face competition

X

Sanofi’s Darzalex rival hits the mark in phase 3 trial

https://pharmaphorum.com/news/sanofis-darzalex-rival-hits-the-mark-in-phase-3-trial/

Sanofi gets opt-in rights to two Regeneron cancer drugs

Sanofi gets opt-in rights to two Regeneron cancer drugs

Sanofi and Regeneron have restructured and extended their immune-oncology discovery and development agreement, giving the French drugmaker rights

X

Sanofi gets opt-in rights to two Regeneron cancer drugs

https://pharmaphorum.com/news/sanofi-gets-opt-in-rights-to-two-regeneron-cancer-drugs/

ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer

ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer

The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance

X

ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer

https://pharmaphorum.com/views-analysis-oncology/asco-round-up-bluebird-bios-car-t-plus-lynch-syndrome-screening/

NICE must be reformed – Janssen UK market access chief

Janssen’s UK pricing chief Jennifer Lee has called for reform of NICE following the company’s successful but drawn-out attempt to get its cancer drug Darzalex to NHS patients.

X

NICE must be reformed – Janssen UK market access chief

https://pharmaphorum.com/news/nice-must-reformed/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com